Catalyst Pharmaceuticals
Mary Coleman has extensive experience in investor relations and corporate communications within the pharmaceutical and biotechnology industries. Currently serving as Vice President and Head of Investor Relations at Catalyst Pharmaceuticals, Inc. since 2021, previous roles include Vice President of Investor Relations at BioXcel Therapeutics, Inc. and Vice President and Head of Investor Relations at Jubilant Pharma. Additional experience includes leading investor relations and corporate communications at BioDelivery Sciences International, Agile Therapeutics, and Savient Pharmaceuticals, among others. Mary Coleman began their career in communications at Wolters Kluwer and 3 Dimensional Pharmaceuticals, and holds a Bachelor's degree from Bowling Green State University as well as post-graduate studies from Washington University in St. Louis.
This person is not in any teams
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.